NCEC and OURAY Announce Integrated Emergency Response Support for the Global Market
NCEC, the chemical experts arm of the Ricardo Group, is partnering with OURAY, a global environmental, engineering, manufacturing, and chemical services company, to offer Level One emergency response to OURAY customers, with an emphasis on the Americas and Asia-Pacific regions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005770/en/
The National Chemical Emergency Centre (NCEC) (Photo: Business Wire)
OURAY’s customers will receive vital telephone-based advice from the experienced NCEC team in the event of a chemical emergency.
The agreement underpins the APAC Emergency Response initiative, which is due to start in January from OURAY’s new Singapore base, to provide a chemical response service for the Asia-Pacific region. The telephone emergency response (Level 1) will be carried out by NCEC’s best-in-class emergency response service. The on-site expert advice (Level 2) and the on-ground responder (Level 3) service will be provided by OURAY.
Jon Gibbard, Director of NCEC, said: “We have an experienced team of responders who are able to ask appropriate questions to understand the context of the scene, and alongside other sources of information such as SDSs, Chemdata and the responders’ own knowledge, they are able to give proportionate, actionable advice to the caller at the scene of the incident.”
Aaron Montgomery, CHMM/OURAY President and CEO, said: “OURAY is extremely excited about offering these combined services to the marketplace. This OURAY/NCEC partnership will allow our organisations to be the first in the world to provide combined Level 1, 2 and 3 services. This signifies a large step forward in OURAY’s mission to be a complete turn-key solution to the global chemical supply chain.”
Mr Gibbard said: “It is a great opportunity for NCEC/OURAY to support customers with best-in-class emergency response services within the Americas and Asia-Pacific region. We are excited to be working with OURAY. This holistic approach to emergency response further supports our vision to create a world fit for the future by reducing harm from incidents globally. This partnership is a clear indication of how NCEC’s advice-focused approach to emergency response is valued within the market. We are all looking forward to getting started.”
Information for editors
About NCEC
NCEC, part of Ricardo, is a leading provider of chemical emergency response and chemical regulatory support services, enabling customers to reduce the impact their activities have on people and the environment, while protecting their reputation and assets. Offering telephone emergency response, regulatory compliance and policy consultation and hazardous material (hazmat) training, NCEC is the first choice for some of the largest chemical companies across the globe. For more information, visit https://the-ncec.com/
About OURAY
OURAY is a leading and global environmental, engineering, manufacturing and chemical services company, offering solutions in over 100 countries. OURAY helps clients reach their long-term goals, by utilising its knowledge and experience across their global network to assist them with their most pressing needs.
https://www.OURAYservices.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005770/en/
Contact information
Julie Palmer
Marketing and Communications, Ricardo Energy & Environment
Tel: 01235 753467
Email: Julie.palmer@ricardo.com
Gill Gibbons
Ricardo Media Office
Tel: +44 (0)7795 342804
E-mail: media@ricardo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom